Stock(600222)Hot line:010-61006450

About

Come and join us in the new era of pharmaceutical industry!

Company Introduction

Stock(600222)
  • 2005

    Founded in 2005

  • 1300+

    Researchers

  • TOP10

    Top 10 Chinese pharmaceutical R & D companies

Leadingpharm was established in 2005 and was listed on the Shanghai Stock Exchange in 2015 (stock code: 600222). It is a high-tech enterprise providing pharmacy preclinical research, clinical CRO and CDMO services to the world. It has been rated as one of the "Top Ten Chinese Pharmaceutical R&D Companies (ranked No. 1 in 2019/2020)" for many years.
 

At present, Leadingpharm has established cooperative relations with more than 500 upstream and downstream enterprises at home and abroad. We have undertaken more than 600 projects of pharmaceutical R&D and more than 500 clinical research projects, applied for more than 200 patents, and obtained nearly 100 authorizations.


From the beginning of its establishment, Leadingpharm took "We make China a world-class player in pharmaceutical technology and production process" as the enterprise vision.and is committed to promoting the development of China's pharmaceutical industry with innovative R&D and service models and information technology!

Headquartered in Beijing Zhongguancun Hi-tech Park, Leadingpharm has a 10000 square meters research and development  laboratory, a R&D team with over 1300 people. It can undertake API synthesis, preparation R&D, analysis and testing, project approval, registration, IVIVR and other businesses, led by technological innovation to R&D. We Establish a high-end API R&D base in Miyun, with a laboratory area of 2,000 square meters, which can conduct high-end excipient imitation and substitution research. In Zhengzhou Linkong Biopark investment Zhengzhou CDMO base, including macromolecular CDMO platform, small molecule CDMO platform (compliant with FDA, EMA and NMPA GMP standards) and Zhengzhou Research Institute Branch (responsible for solid and liquid dosage formulation R&D). In Chongqing investment high-end preparation R&D and MAH base, which has a 4,000-square-meter R&D laboratory, responsible for high-end solid preparation and innovative drug, and can provide MAH related business. In Hangzhou investment the first high-end pediatric drug preparation research institute in China, focusing on the children's drugs R&D, comprehensively covering pharmaceutical research and in vivo and in vitro evaluation in the fields of high-end children's drugs such as chemical drugs, traditional Chinese medicine, and biological drugs.With a mature and complete drug research and development management system, rich project experience, and a team of more than 1000 senior experts at home and abroad, as well as the CXO Whole Industry Chain Service System covering innovative drugs, high-end complex preparations, cell gene therapy drugs and other fields, Leadingpharm can provide global customers with a truly one-stop service.